FDA OKs new blood collection device

The Food and Drug Administration granted market clearance to Seventh Sense Biosystems' new push-button blood collection device.

The device, called Tap, collects capillary blood for hemoglobin A1c testing, which is commonly used to monitor blood sugar levels in diabetic or pre-diabetic patients, according to a news release.

To draw blood, clinicians position the device on a patient's upper arm and "with just a 'tap', blood is collected," according to the company's website.

Seventh Sense Biosystems' said it's working with the FDA to offer additional blood testing options, along with an "at home" collection of products.

The Medford, Mass.-based company will launch Tap in the next few months.

More articles on supply chain:

6 must-reads for supply chain leaders this week
UPS to offer Saturday ground delivery services
FDA approves new liquid drug for hypothyroidism

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars